Form 4 for CTSO Cytosorbents Corp
Accepted 2023-12-15 00:00:00 ET · period of report 2023-12-13 · accession 0001104659-23-126427 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-15 | 2023-12-13 | CTSO | BLOCH KATHLEEN P. | CFO | P - Purchase | $1.33 | +37.6K | 467.9K | +9% | +$50.0K |
| D | 2023-12-15 | 2023-12-13 | CTSO | BLOCH KATHLEEN P. | CFO | P - Purchase | — | +13.2K | 13.2K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-13 | P | A | 37,594 | $1.33 | 467,941 | D | — | — | (F1) These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant (F3) (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015; (F4) (continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and (F2) Includes: (i) the following restricted stock units ("RSUs") (which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into Common Stock upon vesting: 20,000 RSUs granted on September 18, 2023; (F5) (continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person. |
| 2 | Derivative | Common Stock Warrant (Right to Buy) | 2023-12-13 | P | A | 13,157 | — | 13,157 | D | $2.00 · 2023-12-13 to 2028-12-13 | 13,157 Common Stock | (F1) These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant |